Delving into the Latest Updates on SA-ANP with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms

mANP

Target

Aldosterone

Action

antagonists

Mechanism

Aldosterone antagonists

Therapeutic Areas

Cardiovascular DiseasesUrogenital Diseases

Active Indication

Resistant hypertensionChronic Kidney DiseasesHeart failure with normal ejection fraction

Inactive Indication-

Originator Organization

Mayo Clinic

Active Organization

Mayo Clinic

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

This is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing baseline daytime systolic blood pressure (SBP), derived from 24-hour ambulatory blood pressure monitoring (ABPM), in subjects with hypertension who are taking 3 or more antihypertensive medications with different mechanisms of action.

Start Date17 Nov 2024

Sponsor / Collaborator

E-Star BioTech, LLC

[+3]

NCT05279742

/ Enrolling by invitationPhase 1/2IIT

Enhancing the Natriuretic Peptide System in HFpEF: a Randomized Double-Blind Placebo-Controlled Triple Crossover Study

The purpose of this study is to look at the differences in how individuals with heart failure with preserved ejection fraction in the presence of chronic kidney disease (HFpEF-CKD) and exercise induced dyspnea without objective findings of fluid retention (HFpEF-EI) bodies function using drugs Sacubatril/Valsartan (Entresto) and MANP.

Start Date04 Nov 2022

Sponsor / Collaborator

Mayo Clinic

NCT05247528

/ CompletedPhase 1

A Phase 1B, Multiple Ascending Dose Trial Examining The Safety And Tolerability Of Subcutaneous MANP In Difficult To Control/Resistant Hypertensive Subjects

A randomized, double-blind, placebo-controlled multiple ascending dose study in hypertensive subjects on stable doses of at least three hypertensive drugs for at least 6 weeks prior to Screening. The study will consist of screening, PK-unit admittance, and safety follow up periods.
Subjects will be randomized at a 6:2 ratio of either MANP or placebo and will be stratified by race in each dosage cohort. The entire first Cohort will be given the lowest dosage with subsequent cohorts progressing sequentially to the higher doses depending on safety and tolerability of the previous cohort.
Endpoints not related to the safety reviews will be analyzed after the last patient last visit (LPLV).

Start Date20 Dec 2021

Sponsor / Collaborator

E-Star BioTech, LLC

[+2]

100 Clinical Results associated with SA-ANP

Login to view more data

100 Translational Medicine associated with SA-ANP

Login to view more data

100 Patents (Medical) associated with SA-ANP

Login to view more data

13

Literatures (Medical) associated with SA-ANP

01 Jan 2023·Frontiers in chemistry

Green synthesis of MgO nanoparticles and its antibacterial properties.

Article

Author: Ashgar, Sami S. ; Manjunath, Ramya ; Babalghith, Ahmad O. ; Rotti, Rajeshwari B. ; Abdulaziz, Osama ; Mayegowda, Shilpa Borehalli ; Gnanaprakash, A. P. ; Alghamdi, Saad ; Sunitha, D. V. ; El-Lateef, Amal Ezzat Abd ; Allahyani, Mamdouh ; Alsaiari, Ahad Amer ; Roy, Arpita ; Almehmadi, Mazen ; Khidir, Elshiekh B. ; Aljuaid, Abdulelah

Magnesium oxide nanostructured particles (NP) were prepared using a simple solution combustion technique using different leaf extracts such as Mangifera indica (Mango - Ma), Azadirachta indica (Neem-Ne), and Carica papaya (Papaya-Pa) as surfactants. The highly crystalline phase of MgO nanostructures was confirmed by PXRD and FTIR studies for 2 h 500°C calcined samples. To analyze the characteristics of obtained material-MaNP, NeNP, and PaNP for dosimetry applications, thermoluminescence (TL) studies were carried out for Co-60 gamma rays irradiated samples in the dose range 10-50 KGy; PaNP and NeNP exhibited well-defined glow curve when compared with MaNP samples. In addition, it was observed that the TL intensity decreases, with increase in gamma dose and the glow peak temperature is shifted towards the higher temperature with the increase in heating rate. The glow peak was segregated using glow curve deconvolution and thermal cleaning method. Kinetic parameters estimated using Chen's method, trap depth (E), and frequency factor (s) were found to be 0.699, 7.408, 0.4929, and 38.71, 11.008, and 10.71 for PaNP, NeNP, and MaNP respectively. The well-resolved glow curve, good linear behavior in the dose range of 10-50, KGy, and less fading were observed in PaNP as compared with MaNP and NeNP. Further, the antibacterial activity was checked against human pathogens such as Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa. A visible zone of clearance was observed at 200 and 100 μg/mL by the PaNP and NeNP, indicating the death of colonies by the nanoparticles. Therefore, PaNP nanomaterial is a potential phosphor material for dosimetry and antibacterial application compared to NeNP and MaNP.

01 Aug 2022·Hypertension

MANP Activation Of The cGMP Inhibits Aldosterone Via PDE2 And CYP11B2 In H295R Cells And In Mice

Article

Author: Pellegrini, Manuela ; Burnett, John C. ; Naro, Fabio ; Nikolaev, Viacheslav O. ; Chen, Yang ; Cardarelli, Silvia ; Lee, Hon-Chi ; Ma, Xiao ; Iyer, Seethalakshmi R.

Background:Aldosterone is a critical pathological driver for cardiac and renal diseases. We recently discovered that mutant atrial natriuretic peptide (MANP), a novel atrial natriuretic peptide (ANP) analog, possessed more potent aldosterone inhibitory action than ANP in vivo. MANP and natriuretic peptide (NP)-augmenting therapy sacubitril/valsartan are under investigations for human hypertension treatment. Understanding the elusive mechanism of aldosterone inhibition by NPs remains to be a priority. Conflicting results were reported on the roles of the pGC-A (particulate guanylyl cyclase A receptor) and NP clearance receptor in aldosterone inhibition. Furthermore, the function of PKG (protein kinase G) and PDEs (phosphodiesterases) on aldosterone regulation are not clear.Methods:In the present study, we investigated the molecular mechanism of aldosterone regulation in a human adrenocortical cell line H295R and in mice.Results:We first provided evidence to show that pGC-A, not NP clearance receptor, mediates aldosterone inhibition. Next, we confirmed that MANP inhibits aldosterone via PDE2 (phosphodiesterase 2) not PKG, with specific agonists, antagonists, siRNA silencing, and fluorescence resonance energy transfer experiments. Further, the inhibitory effect is mediated by a reduction of intracellular Ca2+ levels. We then illustrated that MANP directly reduces aldosterone synthase CYP11B2 (cytochrome p450 family 11 subfamily b member 2) expression via PDE2. Last, in PDE2 knockout mice, consistent with in vitro findings, embryonic adrenal CYP11B2 is markedly increased.Conclusions:Our results innovatively explore and expand the NP/pGC-A/3',5', cyclic guanosine monophosphate (cGMP)/PDE2 pathway for aldosterone inhibition by MANP in vitro and in vivo. In addition, our data also support the development of MANP as a novel ANP analog drug for aldosterone excess treatment.

01 Apr 2022·HypertensionQ1 · MEDICINE

MANP (M-Atrial Natriuretic Peptide) Reduces Blood Pressure and Furosemide-Induced Increase in Aldosterone in Hypertension

Q1 · MEDICINE

Article

Author: Dzhoyashvili, Nina A. ; Burnett, John C. ; Chen, Horng H. ; Iyer, Seethalakshmi R.

Background:cGMP MANP (M-atrial natriuretic peptide) is a best-in-class activator of the pGC-A (particulate guanylyl cyclase A) receptor. Furosemide increases the effectiveness of antihypertensive agents, but activates renin-angiotensin-aldosterone system. We aimed to investigate for the first time cardiorenal and neurohumoral actions of MANP in a genetic model of hypertension in spontaneously hypertensive rats. We also assessed how MANP would potentiate the blood pressure (BP)–lowering actions of furosemide while reducing the production of aldosterone.Methods:Spontaneously hypertensive rats (N=60) were randomized in vehicle, MANP, furosemide, or MANP+furosemide groups. Furosemide (1, 5, 10 mg/kg) was given as a single bolus which in MANP+furosemide groups was followed by a 60-minute infusion of MANP.Results: BP was reduced in MANP300 (300 pmol/[kg·min]) and MANP600 (600 pmol/[kg·min]) groups ( P <0.05) and was accompanied by significant increase in plasma cyclic guanosine monophosphate. Furosemide alone reduced BP but less compared with MANP with no change in plasma cyclic guanosine monophosphate. MANP+furosemide resulted in the greatest BP reduction and significant increase in plasma cyclic guanosine monophosphate in Fs5+MANP300, Fs10+MANP300, and Fs10+MANP600. Plasma aldosterone increased in furosemide groups, which was significantly attenuated in MANP+furosemide groups. Natriuresis and diuresis increased in all treated groups ( P <0.05) with no significant differences between furosemide and furosemide+MANP. In vitro, MANP increased cyclic guanosine monophosphate level in human vascular cells. Conclusions:We provide novel evidence that MANP potentiates the BP-lowering actions of furosemide, suppresses the activation of renin-angiotensin-aldosterone system, and preserves renal function. These data are highly relevant to clinical needs in the treatment of hypertension and heart failure.

100 Deals associated with SA-ANP

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Resistant hypertension	Phase 2	United States	Mayo Clinic	17 Nov 2024
Chronic Kidney Diseases	Phase 2	United States	Mayo Clinic	04 Nov 2022
Heart failure with normal ejection fraction	Phase 2	United States	Mayo Clinic	04 Nov 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESC2024	Phase 1	Resistant hypertension	36	MANP	sedeyfloco(vqvazgudcu) = There were no reported drug related serious adverse events dxugsfobjf (zelozboutn ) View more	Positive	30 Aug 2024
				Placebo
NCT03781739 (ESC2023)	Phase 1	Metabolic Syndrome \| Hypertension	22	MANP	oktyomeqbw(iimqxzcsqa) = dlmaehnnmh zfjakbjthi (gexfoavqjh ) View more	-	26 Aug 2023
ESC2016	Phase 1	Hypertension	-	ZD100	vwjsnkekaz(tkahqcjpum) = vngvkbyreq dubvbfhfwj (adttgjtujk ) View more	-	28 Aug 2016
				Placebo	wckxkrtmnv(zwxghwofet) = nkefuvhnja rnjisidxqm (odsqtelxca ) View more